Erratum: Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment (Menopause (2015) 22 (1045-1052) DOI: 10.1097/GME.0000000000000430);Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment

Menopause

Volumn 22, Issue 10, 2015, Pages 1045-1052

  Shea, Karen L ^a   Gavin, Kathleen M ^a   Melanson, Edward L ^a   Gibbons, Ellie ^a   Stavros, Anne ^a   Wolfe, Pamela ^b   Kittelson, John M ^b   Vondracek, Sheryl F ^b   Schwartz, Robert S ^a   Wierman, Margaret E ^a   Kohrt, Wendy M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Body composition; Bone mineral density; Fat mass; Fat free mass; Menopause; Resistance exercise

Indexed keywords

ESTRADIOL; GONADORELIN AGONIST; PLACEBO; SEX HORMONE; CONJUGATED ESTROGEN; GONADORELIN;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; CONTROLLED STUDY; FAT FREE MASS; FAT MASS; FEMALE; FEMUR; HUMAN; HUMAN EXPERIMENT; INTRAABDOMINAL FAT; LUMBAR SPINE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; AGONISTS; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; EXERCISE; OVARY; TREATMENT OUTCOME;

ADULT; BODY COMPOSITION; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); EXERCISE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARY; TREATMENT OUTCOME;

EID: 84940455996     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000001056     Document Type: Erratum

References (41)

1. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522-2525.
2. Douchi T, Kuwahata R, Yamasaki H, et al. Inverse relationship between the changes in trunk lean and fat mass during gonadotropin-releasing hormone agonist therapy. Maturitas 2002;42:31-35.
3. Douchi T, Kuwahata T, Yoshimitsu N, Iwamoto I, Yamasaki H, Nagata Y. Changes in serum leptin levels during GnRH agonist therapy. Endocr J 2003;50:355-359.
4. Dumesic DA, Abbott DH, Eisner JR, et al. Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women. Fertil Steril 1998;70:94-101.
5. Revilla R, Revilla M, Villa LF, Cortes J, Arribas I, Rico H. Changes in body composition in women treated with gonadotropin-releasing hormone agonists. Maturitas 1998;31:63-68.
6. Yamasaki H, Douchi T, Yamamoto S, Oki T, Kuwahata R, Nagata Y. Body fat distribution and body composition during GnRH agonist therapy. Obstet Gynecol 2001;97:338-342.
7. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997;82:1549-1556.
8. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001;39:125-132.
9. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180-1185.
10. Hassager C, Christiansen C. Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women. Metabolism 1989;38:662- 665.
11. Jensen LB, Vestergaard P, Hermann AP, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 2003;18:333- 342.
12. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9.
13. Kohrt WM, Ehsani AA, Birge SJ Jr. HRT preserves increases in bone mineral density and reductions in body fat after a supervised exercise program. J Appl Physiol 1998;84:1506-1512.
14. Kristensen K, Pedersen SB, Vestergaard P, Mosekilde L, Richelsen B. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol 1999;163:55-62.
15. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187.
16. Mattiasson I, Rendell M, Tornquist C, Jeppsson S, Hulthen UL. Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res 2002;34:583-588.
17. Utian WH, Gass ML, Pickar JH. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause 2004;11:306-314.
18. Walker RJ, Lewis-Barned NJ, Sutherland WH, et al. The effects of sequential combined oral 17b-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause 2001; 8:27-32.
19. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 1998;9:473-481.
20. Sirola J, Kroger H, Honkanen R, et al. Factors affecting bone loss around menopause in women without HRT: a prospective study. Maturitas 2003;45:159-167.
21. Wu F, Ames R, Clearwater J, Evans MC, Gamble G, Reid IR. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf) 2002;56:703-711.
22. Nowicki M, Adamkiewicz G, Bryc W, Kokot F. The influence of luteinizing hormone-releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma. Am J Obstet Gynecol 2002;186:340-344.
23. Tiidus PM, Lowe DA, Brown M. Estrogen replacement and skeletal muscle: mechanisms and population health. J Appl Physiol 2013; 115:569- 578.
24. Moran AL, Nelson SA, Landisch RM, Warren GL, Lowe DA. Estradiol replacement reverses ovariectomy-induced muscle contractile and myosin dysfunction in mature female mice. J Appl Physiol 2007;102:1387-1393.
25. Lowe DA, Baltgalvis KA, Greising SM. Mechanisms behind estrogen's beneficial effect on muscle strength in females. Exerc Sport Sci Rev 2010;38:61-67.
26. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985-994.
27. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013;369:1011-1022.
28. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor - a knockout mice. Proc Natl Acad Sci U S A 2000;97:12729-12734.
29. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes 2008;32:949-958.
30. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) 2010;18:604-610.
31. Franke HR, van de Weijer PH, Pennings TM, van der Mooren MJ. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril 2000; 74:534-539.
32. Moghissi KS, Schlaff WD, Olive DL, Skinner MA, Yin H. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998;69:1056-1062.
33. Roux C, Pelissier C, Listrat V, et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporos Int 1995;5:185-190.
34. Palomba S, Morelli M, Di Carlo C, Noia R, Pellicano M, Zullo F. Bone metabolism in postmenopausal women who were treated with a gonadotropin- releasing hormone agonist and tibolone. Fertil Steril 2002;78: 63-68.
35. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988;67:701-706.
36. Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol (Oxf) 1988;29:45-51.
37. Paoletti AM, Serra GG, Cagnacci A, et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 1996;65:707-710.
38. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol 2010;22:283-288.
39. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
40. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
41. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.